Canada Markets open in 4 mins
  • S&P/TSX

    20,101.38
    -389.63 (-1.90%)
     
  • S&P 500

    3,923.68
    -165.17 (-4.04%)
     
  • DOW

    31,490.07
    -1,164.52 (-3.57%)
     
  • CAD/USD

    0.7807
    +0.0047 (+0.6074%)
     
  • CRUDE OIL

    106.65
    -2.94 (-2.68%)
     
  • BTC-CAD

    37,927.27
    -140.11 (-0.37%)
     
  • CMC Crypto 200

    659.04
    -11.64 (-1.74%)
     
  • GOLD FUTURES

    1,839.90
    +24.00 (+1.32%)
     
  • RUSSELL 2000

    1,774.85
    -65.45 (-3.56%)
     
  • 10-Yr Bond

    2.7850
    -0.1010 (-3.50%)
     
  • NASDAQ futures

    11,860.25
    -75.25 (-0.63%)
     
  • VOLATILITY

    31.88
    +5.78 (+22.15%)
     
  • FTSE

    7,266.11
    -171.98 (-2.31%)
     
  • NIKKEI 225

    26,402.84
    -508.36 (-1.89%)
     
  • CAD/EUR

    0.7400
    -0.0013 (-0.18%)
     

ImmunoPrecise Antibodies Announces Grant of Stock Options

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

VICTORIA, British Columbia, January 17, 2022--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that on January 13, 2022 its board of directors approved the grant of 15,000 stock options (the "Options") under its stock option plan to acquire up to an aggregate of 15,000 common shares in the capital of IPA ("Common Shares"). The Options were granted to a certain officer of IPA. Each Option is exercisable for a period of six months from the date of grant at an exercise price of Cdn $8.30 per Common Share. One third of the Options granted to the officer will vest every two months from the date of grant.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For further information, visit www.immunoprecise.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220117005124/en/

Contacts

LifeSci Advisors
John Mullaly
Email: jmullaly@lifesciadvisors.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting